DYN

Dyne Therapeutics, Inc. (DYN) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Dyne Therapeutics is a clinical-stage neuromuscular disease company focused on its proprietary FORCE platform, which delivers targeted therapeutics to muscle tissue and the central nervous system. The company has no approved products and has not generated any revenue from product sales. Its primary activities involve the research and development of product candidates for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral dystrophy (FSHD), and Pompe disease.

Key Financial Metrics

Note: Q1 2025 cash balance is not explicitly stated in the comparative table, but the beginning balance for Q1 2026 was $895,740 (including restricted cash).

Material Changes vs. Prior Period

• Debt Financing: The company entered into a Loan Agreement with Hercules Capital, Inc. in June 2025. As of March 31, 2026, the principal term loan balance was $150.0 million, resulting in $4.2 million of interest expense for the quarter. No interest expense was recorded in Q1 2025.
• Operating Expenses: Total operating expenses increased by $2.9 million to $125.3 million.
  • R&D Expenses: Decreased by $5.6 million to $100.9 million. This was driven by a $30.7 million decrease in expenses for z-basivarsen (DM1), partially offset by a $16.7 million increase in expenses for z-rostudirsen (DMD) due to manufacturing activity and Phase 3 start-up costs.
  • G&A Expenses: Increased by $8.5 million to $24.4 million, primarily due to increased headcount (34 new employees) and higher professional fees related to launch preparations.
• Cash Flow: Net cash used in operating activities increased to $144.9 million from $105.9 million in the prior year, largely due to a $32.8 million increase in prepaid expenses. Net cash provided by financing activities was $7.1 million, compared to $141.2 million in Q1 2025, as the company did not issue shares under its at-the-market offering program in the current quarter.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($972.2 million) will fund operations, debt service, and capital expenditures into the first quarter of 2028.
• Development Milestones:
  • z-rostudirsen (DMD): Plans to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026. A global confirmatory Phase 3 trial is planned to initiate in Q2 2026. Potential U.S. launch expected in Q1 2027.
  • z-basivarsen (DM1): Enrollment in the registrational expansion cohort is expected to complete in Q2 2026. Data announcement expected in Q1 2027 to support a potential BLA submission in Q3 2027. Potential U.S. launch expected in Q1 2028.
• Debt Covenants: The Loan Agreement includes a "Minimum Cash Covenant" effective January 1, 2027, requiring the company to maintain cash levels at 60% of the outstanding principal balance. It also includes a "Minimum Revenue Covenant" triggered nine months after FDA approval if debt exceeds $100 million.
• Risks: Key risks include the need for substantial additional funding, the unproven nature of the FORCE platform, potential delays in clinical trials, and the impact of U.S. trade policy and tariffs on supply chains. The company faces significant competition in DMD and DM1 markets.

Investor Verification Checklist

• Verify the company's ability to meet the Minimum Cash Covenant starting January 1, 2027, given the $150 million debt principal.
• Monitor the timeline for the z-rostudirsen BLA submission in Q2 2026 and the initiation of the Phase 3 trial.
• Assess the impact of manufacturing costs, which are projected to represent 55-65% of total R&D expenses for the full year 2026.
• Review the status of the vendor financing arrangement ($6.2 million outstanding) and its repayment terms.
• Track the cash burn rate relative to the $972 million liquidity position to confirm the runway into Q1 2028.